Efficacy and safety of pegylated interferon in children and adolescents infected with chronic Hepatitis C: A preliminary study

Journal of Pharmacy Practice

Volumn 24, Issue 2, 2011, Pages 203-210

  Abdel Aziz, Doa'A Hamed ^a   Sabry, Nirmeen Ahmed ^b   El Sayed, Manal Hamdy ^c   El Gazayerly, Omima Naiem ^b  

^a National Hepatology and Tropical Medicine Research Institute NHTMRI   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

chronic hepatitis C infection; pediatrics; pegylated interferon; ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CHILL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EGYPT; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; INJECTION SITE REACTION; LEUKOPENIA; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; RELAPSE; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD; VOMITING;

EID: 79955570518     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010367737     Document Type: Article

References (40)

1. http://www.epidemic.org/theFacts/theEpidemic/worldPrevalence.
2. Geneva, Switzerland: WHO ; 1998 :
3. Management of hepatitis C. Hepatology. 1997 ; 26: 28-108
4. Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971-1975. Hepatology. 2000 ; 32: 582-587
5. Arthur RR, Hassan NF, Abdullah MY, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg. 1997 ; 91: 271-274 (Pubitemid 27261161)
6. Nafeh MA, Medhat A, Shehata M, et al. Hepatitis C in a community in upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg. 2000 ; 63: 236-241 (Pubitemid 32537556)
7. El-Zayadi AR, Selim O, Ibrahim EH, et al. Does schistosomiasis play a role in the high sero prevalence of HCV antibody among Egyptians?. Trop Gastroenterol. 1997 ; 18: 98-100
8. Habib M, Mohamed MK, Abdelaziz F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology. 2001 ; 33: 248-253 (Pubitemid 32016908)
9. Hassan MM, Zaghloul AS, El-Serag HB, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol. 2001 ; 33: 123-126 (Pubitemid 32685921)
10. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 ; 341: 556-562 (Pubitemid 29384163)
11. Mohamed MK. Epidemiology of HCV in Egypt 2004. Afro Arab Liver J. 2004 ; 3: 41-52
12. Goldman R, Ressom HW, Abdelhamid M, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis. 2007 ; 28: 2149-2153 (Pubitemid 47543375)
13. Tong MJ. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995 ; 332: 1463-1466
14. Fried M. Therapy of hepatitis C. Semin Liver Dis. 1995 ; 15: 82-91
15. Poynard T, Marcellin P, Lee SS, et al. Randomised study of INF alpha2b plus ribavirin for 48 weeks or for 24 weeks versus INF alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998 ; 352: 1426-1432 (Pubitemid 28510876)
16. McHutchison JG, Gordon SC, Schiff ER, et al. INF alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998 ; 339: 1485-1492 (Pubitemid 28543496)
17. http://www.fda.gov/OHRMS/DOCKETS/ac/cder98t.htm
18. Consensus Statement: EASL International Consensus Conference on Hepatitis C. J Hepatol. 1999 ; 30: 956-961
19. http://emedicine.medscape.com/article/177792-overview..
20. Consensus conference: treatment of hepatitis C. Gastroenterol Clin Biol. 2002 ; 26: B303 - B319
21. Consensus Development Conference Statement: Management of Hepatitis C. Bethesda, MD: National Institutes of Health ; 2002 :
22. Michielsen P, Brenard R, Bourgeois N, et al. Hepatitis C: Screening, treatment and prevention. Practical guidelines. Acta Gastroenterol Belg. 2003 ; 66: 15-19 (Pubitemid 36307053)
23. Jonas M. Interferon-alpha for viral hepatitis. J Pediatr Gastroenterol Nutr. 1996 ; 23: 93-106
24. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005 ; 41: 1013-1018 (Pubitemid 40593909)
25. Baker RD, Dee D, Baker SS. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol. 2007 ; 41: 111-114 (Pubitemid 46045679)
26. http://www.wma.net/e/policy/pdf/17c.pdf..
27. CPMP/ICH/135/95, July. http://www.emea.europa.eu/pdfs/human/ich/013595en. pdf..
28. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981 ; 47: 207-214 (Pubitemid 11167383)
29. Calis JC, Van Hensbroek MB, de Haan RJ, et al. HIV-associated anemia in children: a systematic review from a global perspective. AIDS. 2008 ; 22: 1099-1112
30. http://www.neutropenia.ca/about/index.html..
31. Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology. 1998 ; 28: 1416-1423 (Pubitemid 28493855)
32. Bortolotti F, Jara P, Diaz C, et al. Posttransfusion and community-acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr. 1994 ; 18: 279-283 (Pubitemid 24125837)
33. Schwarz KB, Mohan P, Narkewiez MR, et al. Safety, efficacy and pharmacokinetics of Peginterferon alpha 2a (40kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2007 ; 43: 499-504
34. Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009 ; 49: 358-363
35. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, et al. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiol Drug Saf. 2007 ; 16: 1095-1103 (Pubitemid 350020062)
36. Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002 ; 36: 1280-1284 (Pubitemid 35253447)
37. Christensson B, Wiebe T, Akesson A, et al. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis. 2000 ; 30: 585-586 (Pubitemid 30205310)
38. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics. 2000 ; 106: E53
39. Suoglu OD, Elkabes B, Sokucu S, et al. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C?. J Pediatr Gastroenterol Nutr. 2002 ; 34: 199-206 (Pubitemid 34259643)
40. Gonzalez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005 ; 42: 1010-1018 (Pubitemid 43112667)